text_1: 90% of patients with melanoma and an objective response to PD-1 blockade will experience a progression in their melanoma.
text_2: IMPORTANCE The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab.